Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
- Nesina Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
October 3, 2011
- Toyobo Biologics Partners with Catalent to Strengthen Contract Manufacturing Business
October 3, 2011
- MSD, Hisamitsu to Terminate Copromotion of Fosamac in February 2012
October 3, 2011
- Barclays Raises MTPC’s Target Share Price on Telavic Survey
October 3, 2011
- Support of Gov’t, Industry Essential for Development of RNA-based Drugs: PMRJ Seminar
October 3, 2011
- SGLT2 Inhibitor Ipragliflozin Significantly Reduced HbA1c in PIII Study: Astellas
October 3, 2011
- Weight Gain with Lantus Lowest in Patients with HbA1c Below 8%: Sanofi
October 3, 2011
- NBI, Eli Lilly Japan: DPP-4 Inhibitor Trazenta Tablets 5 mg for Type 2 Diabetes
October 3, 2011
- Pfizer Starts New Online Promotion with MedPeer
September 30, 2011
- MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
- Takeda Files NDA for Hyperlipidemia Treatment TAK-085 in Japan
September 30, 2011
- Imatinib Significantly Improves Walking Distance in Patients with PAH: Novartis
September 30, 2011
- Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
- Santen to Acquire French Drugmaker, Strengthen R&D
September 29, 2011
- Ono, Univ. of Tokyo Sign Joint Research Agreement for Drug Discovery Target Identification
September 29, 2011
- MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
- NBI Releases Latest PMS Results for Prazaxa
September 28, 2011
- Rivaroxaban Recommended for Approval in EU: Bayer
September 28, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…